Tech Company Financing Transactions

Gro Biosciences Funding Round

On 7/21/2024, Gro Biosciences raised $60.3 million in Series B funding from Access Biotechnology, Atlas Venture and Digitalis Ventures.

Transaction Overview

Company Name
Gro Biosciences
Announced On
7/21/2024
Transaction Type
Venture Equity
Amount
$60,300,000
Round
Series B
Investors

Access Biotechnology (Lead Investor) (Dan Becker)

Atlas Venture (Lead Investor) (Kevin Bitterman)

Digitalis Ventures (Geoffrey Smith)

Innovation Endeavors

Leaps by Bayer (Jürgen Eckhardt)

Redmile Group

Proceeds Purpose
The company intends to use the funds to advance its lead program into the clinic for the treatment of refractory gout, to broaden the GRObio pipeline, and to expand its genomically recoded organism (GRO) platform for scalable production of therapeutics incorporating multiple non-standard amino acids (NSAAs).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave.
Boston, MA 02134
USA
Phone
(617) 903-8359
Website
www.grobio.com
Email Address
Not Recorded
Overview
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties.
Profile
Gro Biosciences LinkedIn Company Profile
Social Media
Gro Biosciences Company Twitter Account
Company News
Gro Biosciences News
Facebook
Gro Biosciences on Facebook
YouTube
Gro Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Daniel Mandell
  Daniel Mandell LinkedIn Profile  Daniel Mandell Twitter Account  Daniel Mandell News  Daniel Mandell on Facebook
Chief Scientific Officer
Christopher Gregg
  Christopher Gregg LinkedIn Profile  Christopher Gregg Twitter Account  Christopher Gregg News  Christopher Gregg on Facebook
Co-Founder
George Church
  George Church LinkedIn Profile  George Church Twitter Account  George Church News  George Church on Facebook
Co-Founder
Andrew Ellington
  Andrew Ellington LinkedIn Profile  Andrew Ellington Twitter Account  Andrew Ellington News  Andrew Ellington on Facebook
Co-Founder
Marc Lajoie
  Marc Lajoie LinkedIn Profile  Marc Lajoie Twitter Account  Marc Lajoie News  Marc Lajoie on Facebook
Co-Founder
Ross Thyer
  Ross Thyer LinkedIn Profile  Ross Thyer Twitter Account  Ross Thyer News  Ross Thyer on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/21/2024: Antheia venture capital transaction
Next: 7/22/2024: Cell BioEngines venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.